These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28270434)

  • 1. Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
    Campbell-Scherer D
    Evid Based Med; 2017 Apr; 22(2):57-58. PubMed ID: 28270434
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
    Ebell MH
    Am Fam Physician; 2017 Mar; 95(6):396. PubMed ID: 28318215
    [No Abstract]   [Full Text] [Related]  

  • 5. In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
    Lipscombe LL
    Ann Intern Med; 2019 Sep; 171(6):JC28. PubMed ID: 31525762
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Zweck E; Westenfeld R; Szendroedi J
    N Engl J Med; 2019 Nov; 381(21):2075-2076. PubMed ID: 31747739
    [No Abstract]   [Full Text] [Related]  

  • 7. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó R; Hernández C
    Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
    Husain M; Donsmark M; Bain SC
    N Engl J Med; 2019 Nov; 381(21):2076-2077. PubMed ID: 31747740
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
    Abdul-Ghani M; DeFronzo RA; Del Prato S; Chilton R; Singh R; Ryder REJ
    Diabetes Care; 2017 Jul; 40(7):813-820. PubMed ID: 28637886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
    Donato AA
    Ann Intern Med; 2017 Jan; 166(2):JC8. PubMed ID: 28114464
    [No Abstract]   [Full Text] [Related]  

  • 13. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes: Cardiovascular benefits of semaglutide.
    Lim GB
    Nat Rev Cardiol; 2016 Dec; 13(12):697. PubMed ID: 27708277
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide and GLP-1 analogues as weight-loss agents.
    Kluger AY; McCullough PA
    Lancet; 2018 Aug; 392(10148):615-616. PubMed ID: 30122306
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
    Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
    Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.